Browsing: Lipfendra

On July 16, 2026, the Food and Drug Administration (FDA) approved Lipfendra (enlicitide), the first ever oral PCSK9 inhibitor , for the treatment of high cholesterol (hypercholesterolemia) and heterozygous familial hypercholesterolemia